photo of Lenore Goldfarb
recurrent miscarriage

Recurrent fetal death and antiphospholipid antibody syndrome
A case report

Ginecol Obstet Mex 1997 Dec;65:523-8 (ISSN: 0300-9041)
Rojas-Poceros G; Ramirez Peredo J; Hernandez Andrade E; Bustos Lopez HH
Departamento de Esterilidad e Infertilidad, Instituto Nacional de Perinatologia, Mexico D.F.

Antiphospholipid Antibodies has been associated with severe maternal and fetal sequels, like recurrent miscarriage, death, intrauterine growth retardation, pregnancy-induced hypertensive disease, thromboembolic phenomena and thrombocytopenia. Pathogenesis has been explained reporting that IgG from women with antiphospholipid antibodies increases placenta thromboxane production without affecting prostacyclin production, which conducts to thrombosis of placenta uterus junction.

In 1982, it was suggested for the first time low doses of aspirin and prednisone for treatment of recurrent fetal death associated to this syndrome, heparin therapy was reported in 1984, recommended a doses of 15,000 U/day during first pregnancy trimester and 20,000 U/day posteriorly.

The objective of this report, is the description a clinic case of a patient with recurrent fetal death and antiphospholipid antibodies syndrome, discussing a prenatal and obstetric treatment model, including diagnosis and final therapeutic, which includes the participation of some other specialists, the national experience in diagnosis and treatment is initial, and also because it has been reported a rate of fetal death in those patient with no treatment, almost of 90%. The importance of identify this syndrome is not based on its prevalence but on its maternal complications and that it is a cause of fetal death potentially treatable.

print this page back

If you value this service, kindly consider a donation to the Canadian Breastfeeding Foundation (registered charity). Earmark the donation for the International Breastfeeding Centre (Newman Breastfeeding Clinic) and/or the Goldfarb Breastfeeding Program.

Donate online:

Donate by mail: Canadian Breastfeeding Foundation, 5890 Monkland Ave, Suite 16, Montreal, Quebec, Canada H4A 1G2.

© 2002-2019 Lenore Goldfarb, PhD, CCC, IBCLC, ALC and contributing authors to All rights reserved.

Disclaimer: The information provided on this website is for general informational purposes only and does not constitute medical advice. You should not rely on this information as a substitute for, nor does it replace, professional medical advice, diagnosis, or treatment. If you have any specific questions or concerns about any health issue, you should consult with a qualified healthcare provider.
The AskLenore administration is not affiliated with, nor sponsored by, nor do we sell or receive any commissions or incentives from, any of the products or services that we link to on this website. Therefore, we are not responsible for the accuracy, quality, availability, or suitability of said products or services. You should always do your own research and due diligence before purchasing or using any product or service that we link to on this website.
The views and opinions expressed on the message boards are those of the authors and do not necessarily reflect the official policy or position of Any content provided by our users are of their opinion and are not intended to malign any religion, ethnic group, club, organization, company, individual or anyone or anything.